Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.

• Autoři: ŽÁČKOVÁ Daniela; KLAMOVÁ Hana; MUŽÍK Jan; CMUNT Edmund; RÁČIL Zdeněk; MACHOVÁ POLÁKOVÁ Kateřina; DVOŘÁKOVÁ Dana; JURČEK Tomáš; RÁZGA Filip; CETKOVSKÝ Petr; DUŠEK Ladislav; MAYER Jiří
• Rok publikování: 2013
• Druh: Článek v odborném periodiku
• Časopis / Zdroj: Leukemia & Lymphoma
• Fakulta / Pracoviště MU: Středoevropský technologický institut
• www: http://informahealthcare.com/doi/abs/10.3109/10428194.2013.772173
• Doi: http://dx.doi.org/10.3109/10428194.2013.772173
• Obor: Onkologie a hematologie
• Klíčová slova: chronic myeloid leukemia; formal clinical trials; dasatinib; imatinib

Přiložené soubory

• ZVV_1139161_Efficacy_and_tolerance.pdf

• Popis: Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials. Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.